Related Experiment Video
Updated: Jun 28, 2025
03:23
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
745
Exploring novel perspectives on eosinophilic inflammation in severe asthma
Claudio Candia1, Pasquale Ambrosino2, Silvestro E D'Anna2
1Department of Clinical Medicine & Surgery, Federico II University, Naples, 80131, Italy.
Biomarkers in Medicine
|April 16, 2024
Summary
Severe eosinophilic asthma patients have more CD62L-low inflammatory eosinophils (iEos), linked to poor asthma control. These iEos decrease with mepolizumab treatment, suggesting potential as a biomarker.
Area of Science:
- Immunology
- Pulmonology
- Allergy
Background:
- Severe eosinophilic asthma is characterized by elevated eosinophils.
- A specific eosinophil subtype, CD62L-low inflammatory eosinophils (iEos), has been identified.
- Previous research noted a correlation between iEos and asthma control.
Purpose of the Study:
- To investigate the role of CD62L-low inflammatory eosinophils in severe eosinophilic asthma.
- To assess the impact of anti-IL-5 therapy on iEos levels.
- To explore the potential of eosinophil subtypes as biomarkers in asthma management.
Main Methods:
- Analysis of eosinophil subtypes in patients with severe eosinophilic asthma.
- Correlation of iEos proportions with asthma control scores.
- Evaluation of iEos levels before and after treatment with mepolizumab.
Main Results:
- Patients with severe eosinophilic asthma showed a higher proportion of CD62L-low iEos.
- A significant correlation was observed between iEos levels and asthma control.
- Treatment with mepolizumab led to a reduction in CD62L-low iEos.
Conclusions:
- CD62L-low inflammatory eosinophils may serve as a valuable biomarker in severe eosinophilic asthma.
- Monitoring iEos could aid in characterizing patient endotypes.
- Eosinophil subtype analysis may help predict response to biological therapies like mepolizumab.
Related Concept Videos
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:20Asthma: Pathogenesis and Management
391
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
391
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
284
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
284
01:29Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:17Drugs Used in Lower Respiratory Disorders: Overview
428
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
428